Skip to main contentAI and Advanced
/
APLLTD · NSEMarket ticker unavailable · configure an authorised index feed
AP
NSE · Equity shares · Biotechnology & Drugs18.00 · 2.23%
Alembic Pharmaceuticals APLLTD
NSE:INR 825
BSE:INR 835.95
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for APLLTD
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 807
Day rangeINR 810.2 — INR 839.35
52-week rangeINR 635.8 — INR 998
Volume1.65 L
Market cap16,431.7
P/E23.33
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)7,344.9
Net Income (INR Cr)674.77
Rev Growth (5 Year %)6.37
EPS Growth (5 Year %)-10.32
P/E Ratio23.33
EPS37.73
Research path: Interpret Alembic Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
APLLTDAlembic Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 8,762.59 | 7,772.94 | 6,445.58 |
| Accumulated Depreciation Total | -1,809.51 | -1,593.79 | -1,328.5 |
| Other Liabilities Total | 333.1 | 124.31 | 109.5 |
| Accrued Expenses | 92.73 | 84.03 | 89.18 |
| Long Term Debt | 121.92 | Not available | Not available |
| Common Stock Total | 39.31 | 39.31 | 39.31 |
| Other Equity Total | 38.86 | 11.83 | 15.76 |
| Other Current Assets Total | 50.22 | 18.13 | 20.41 |
| Prepaid Expenses | 80.76 | 69.18 | 50.05 |
| Total Assets | 8,762.59 | 7,772.94 | 6,445.58 |
| Current Portof LT Debt/Capital Leases | 44.65 | 15.16 | 19.83 |
| Additional Paid-In Capital | 748.39 | 748.39 | 748.39 |
| Cash | 196.37 | 83.48 | 120.21 |
| Total Equity | 5,674.81 | 5,190.94 | 4,818.2 |
| Long Term Investments | 140.88 | 127.21 | 93.02 |
| Retained Earnings(Accumulated Deficit) | 4,854.32 | 4,394.46 | 4,027.26 |
| Total Common Shares Outstanding | 19.66 | 19.66 | 19.66 |
| Property/Plant/Equipment Total-Gross | 5,286.09 | 4,954.56 | 4,399.56 |
| Tangible Book Valueper Share Common Eq | 274.11 | 264.09 | 245.12 |
| Total Liabilities | 3,087.78 | 2,582 | 1,627.38 |
| Total Debt | 1,429.94 | 1,257.5 | 513.16 |
| Cashand Short Term Investments | 196.37 | 83.48 | 120.21 |
| Total Receivables Net | 1,677.75 | 1,585.68 | 1,186.06 |
| Notes Payable/Short Term Debt | 1,218.61 | 1,195.57 | 430.45 |
| Accounts Receivable-Trade Net | 1,466.3 | 1,399.79 | 1,024.84 |
| Property/Plant/Equipment Total-Net | 3,477.29 | 3,360.76 | 3,071.07 |
| Minority Interest | -5.83 | -1.42 | Not available |
| Total Current Liabilities | 2,593.83 | 2,412.34 | 1,455 |
| Total Inventory | 2,567.49 | 2,331.32 | 1,701.83 |
| Accounts Payable | 835.08 | 879.89 | 735.64 |
| Other Currentliabilities Total | 402.76 | 237.69 | 179.9 |
| Total Long Term Debt | 166.68 | 46.77 | 62.88 |
| Intangibles Net | 286.78 | 0 | 0 |
| Other Long Term Assets Total | 269.62 | 166.03 | 169.63 |
| Note Receivable-Long Term | 15.43 | 31.15 | 33.3 |
| Unrealized Gain(Loss) | -6.07 | -3.05 | -12.52 |
| Total Current Assets | 4,572.59 | 4,087.79 | 3,078.56 |
| Capital Lease Obligations | 44.76 | 46.77 | 62.88 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.91
Price to Sale Ratio2.24
Growth
Debt 5Yr CAGR %19.63
Margins
Operating Margin 12m9.76
Operating Margin 5y Avg10.14
Net Profit Margin 12m8.86
Net Profit Margin 5y8.74
Yield
Dividend Yield %1.47
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk31.8
Analyst consensus
ConsensusBuy
Consensus score2.22
Analyst opinions9
Strong Sell count0
Sell count0
Hold count5
Buy count1
Strong Buy count3
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 69.87%
- FII
- 4.17%
- MF
- 8.73%
- Other
- 17.23%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Alembic Pharma's partner NATCO secures tentative FDA approval for generic Olaparib tablets - Indian Pharma PostMarket news · 19 Jul 2026, 6:30 pm
Alembic Pharma's partner NATCO secures tentative FDA approval for generic Olaparib tablets Indian Pharma Post
USFDA Issues Warning Letter to Clinical Investigator Linked to Alembic Bioequivalence Study - Medical DialoguesMarket news · 15 Jul 2026, 10:20 pm
USFDA Issues Warning Letter to Clinical Investigator Linked to Alembic Bioequivalence Study Medical Dialogues
Alembic Pharma appoints M. Sai Kiran as General Manager – Distribution - Indian Pharma PostMarket news · 14 Jul 2026, 4:49 pm
Alembic Pharma appoints M. Sai Kiran as General Manager – Distribution Indian Pharma Post
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.12.0000 per share(600%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsTo consider other business matters.
- board MeetingsTo consider other business matters.
Rusaka Markets Community
Discussion and sentiment for Alembic Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its Indian Formulations.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- APLLTD
- BSE Code
- 533573
Questions
Stock FAQ
What is the symbol and ISIN of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has the symbol APLLTD and ISIN - INE901L01018.
What is the current price of Alembic Pharmaceuticals?
Alembic Pharmaceuticals is currently trading at INR 825.00.
What are the year high and year low of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a year high of INR 998.00 and a year low of INR 635.80.
What is the market capitalization of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a market capitalization of INR 16,431.70 crore.
What is the P/E ratio of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a P/E ratio of 23.33.
What is the dividend yield of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a dividend yield of 1.47%.
How is the financial performance of Alembic Pharmaceuticals based on revenue, net income, and EPS?
Alembic Pharmaceuticals has revenue of INR 7,344.90 crore, net income of INR 674.77 crore, and EPS of INR 37.84.
What is the book value of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a book value of NA.
What is the debt-to-equity ratio of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Alembic Pharmaceuticals?
Alembic Pharmaceuticals has a price-to-book ratio of NA and a price-to-sales ratio of 2.24.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.